Tag: Term

Dupilumab had an acceptable long-term safety and efficacy for adolescents with moderate to severe atopic dermatitis (AD), according to data from an open-label extension (OLE) phase 3 trial published in the American Journal of Clinical Dermatology. For adolescents (aged 12 to 18 years) with moderate to severe AD enrolled in the LIBERTY AD PED-OLE study, […]